Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy

Breast

Volumn 21, Issue 3, 2012, Pages 276-283

  Wright, J L ^a   Reis, I M ^a   Zhao, W ^a   Panoff, J E ^a   Takita, C ^a   Sujoy, V ^a   Gomez, C R ^a   Jorda, M ^a   Franceschi, D ^a   Hurley, J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor; Racial disparity; Trimodality therapy; Triple negative

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GONADORELIN ANTAGONIST; PLATINUM COMPLEX; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CAUCASIAN; CLIMACTERIUM; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; NEGRO; OVERALL SURVIVAL; POSTMENOPAUSE; POSTOPERATIVE CARE; PREMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER;

EID: 84862535042     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.11.003     Document Type: Article

References (17)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2010, 60:277-300.
2. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728.
3. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
4. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
5. Hugh J., Hanson J., Cheang M.C., Nielsen T.O., Perou C.M., Dumontet C., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27:1168-1176.
6. Kyndi M., Sorensen F.B., Knudsen H., Overgaard M., Nielsen H.M., Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:1419-1426.
7. O'Brien K.M., Cole S.R., Tse C.K., Perou C.M., Carey L.A., Foulkes W.D., et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010, 16:6100-6110.
8. Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28:1684-1691.
9. Dawood S., Broglio K., Kau S.W., Green M.C., Giordano S.H., Meric-Bernstam F., et al. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 2009, 27:220-226.
10. Hurley J, Personal communication; 2009.
11. Anderson W.F., Chu K.C., Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?. J Clin Oncol 2003, 21:2254-2259.
12. Hershman D.L., Kushi L.H., Shao T., Buono D., Kershenbaum A., Tsai W.Y., et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010, 28:4120-4128.
13. Morrow P.K., Serna R., Broglio K., Pusztai L., Nikoloff D.M., Hillman G.R., et al. Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer 2011.
14. Dezentje V.O., Guchelaar H.J., Nortier J.W., van de Velde C.J., Gelderblom H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 2009, 15:15-21.
15. Differences in prevalence of obesity among Black, White, and Hispanic adults - United States, 2006-2008. Morbidity Mortality Weekly Rep 2009, 58(27):740-744.
16. Sestak I., Distler W., Forbes J.F., Dowsett M., Howell A., Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010, 28:3411-3415.
17. Lu Y., Ma H., Malone K.E., Norman S.A., Sullivan-Halley J., Strom B.L., et al. Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol 2011, 29:3358-3365.